Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
10.95
-0.90 (-7.59%)
At close: May 30, 2025, 4:00 PM
10.96
+0.01 (0.09%)
After-hours: May 30, 2025, 4:20 PM EDT
Company Description
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.
Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions.
The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001.
Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Oruka Therapeutics, Inc.
Country | United States |
Founded | 2004 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 28 |
CEO | Lawrence Klein |
Contact Details
Address: 855 Oak Grove Avenue, Suite 100 Menlo Park, California 94025 United States | |
Phone | (650) 606-7910 |
Website | orukatx.com |
Stock Details
Ticker Symbol | ORKA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000907654 |
CUSIP Number | 687604108 |
ISIN Number | US6876041087 |
Employer ID | 36-3855489 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Lawrence Otto Klein Ph.D. | President, Chief Executive Officer and Director |
Paul T. Quinlan | General Counsel and Secretary |
Dr. Joana Goncalves M.D. | Chief Medical Officer |
Arjun Agarwal CPA | Senior Vice President of Finance and Treasurer |
Laura Sandler | Senior Vice President of Operations and Boston Site Head |
Alan Lada | Vice President of Investor Relations |
Christopher Finch | Vice President of Corporate Development and Strategy |
Dr. Rajiv Panwar | Vice President and Head of Chemistry, Manufacturing and Controls |
Dr. Joe Senn Ph.D. | Senior Vice President of Nonclinical Research and Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 15, 2025 | SCHEDULE 13G | Filing |
May 14, 2025 | 424B3 | Prospectus |
May 14, 2025 | 10-Q | Quarterly Report |
May 13, 2025 | SCHEDULE 13G | Filing |
Apr 18, 2025 | ARS | Filing |
Apr 18, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 18, 2025 | DEF 14A | Other definitive proxy statements |
Mar 11, 2025 | EFFECT | Notice of Effectiveness |
Mar 10, 2025 | SCHEDULE 13D/A | Filing |
Mar 6, 2025 | POS AM | Post-Effective amendments for registration statement |